Is Augmentin (amoxicillin-clavulanate) effective in treating Staphylococcus saprophyticus infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Augmentin's Effectiveness Against Staphylococcus saprophyticus

Augmentin (amoxicillin-clavulanate) is effective against Staphylococcus saprophyticus infections, as it is specifically listed in the FDA drug label as one of the organisms susceptible to this antibiotic combination. 1

Mechanism and Coverage

  • Augmentin combines amoxicillin (a semisynthetic antibiotic with bactericidal activity against Gram-positive and Gram-negative bacteria) with clavulanic acid (a beta-lactamase inhibitor) 1
  • Clavulanic acid protects amoxicillin from degradation by beta-lactamase enzymes, extending its spectrum to include many bacteria normally resistant to amoxicillin alone 1
  • The FDA drug label specifically lists Staphylococcus saprophyticus among the organisms for which in vitro data shows susceptibility to amoxicillin/clavulanic acid 1

Clinical Application for S. saprophyticus Infections

  • S. saprophyticus is a common cause of urinary tract infections (UTIs), particularly in young, sexually active women 2, 3
  • Augmentin has demonstrated effectiveness in treating urinary tract infections with a success rate of about 70% for amoxicillin-resistant organisms 2
  • The standard dosage of Augmentin (375 mg three times daily) achieves adequate urinary levels of amoxicillin potentiated by clavulanic acid to treat most Gram-negative urinary pathogens 2

Alternative Treatment Options

For patients who cannot tolerate Augmentin or have resistant infections:

  • Trimethoprim-sulfamethoxazole (TMP-SMX) 160/800 mg twice daily is an effective alternative for S. saprophyticus infections 4
  • Doxycycline 100 mg twice daily can be considered for skin and soft tissue infections involving staphylococci 5
  • For more severe infections, vancomycin 15-20 mg/kg IV every 8-12 hours may be used 6, 4

Important Considerations and Caveats

  • Recent research has raised concerns about the adequacy of empirical antibiotic treatments for UTIs caused by S. saprophyticus, with up to 60% of cystitis cases receiving inappropriate initial therapy 7
  • When treating S. saprophyticus infections, it's important to confirm susceptibility through culture and sensitivity testing 7
  • Augmentin is well-tolerated but may cause gastrointestinal side effects including diarrhea and abdominal pain in some patients 8
  • For complicated infections or pyelonephritis caused by S. saprophyticus, consider initial parenteral therapy before transitioning to oral Augmentin 6

Dosing Recommendations

  • For uncomplicated UTIs: Augmentin 500/125 mg orally twice daily or 250/125 mg orally three times daily for 5-7 days 1, 2
  • For complicated UTIs: Augmentin 875/125 mg orally twice daily for 10-14 days 1, 9
  • For skin and soft tissue infections: Augmentin 875/125 mg orally twice daily for 7-10 days 6

In conclusion, Augmentin is an appropriate choice for treating S. saprophyticus infections, particularly urinary tract infections, due to its specific activity against this organism as confirmed by the FDA drug label and supporting clinical evidence.

References

Guideline

Alternative Antibiotics for MRSA and VRE Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Doxycycline Coverage for Staphylococcus and Streptococcus Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Staphylococcus saprophyticus: Which beta-lactam?

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.